What You Should Know:
– Salvo Health, a company dedicated to improving chronic gut health management raises $5M in seed funding led by City Light Capital and Human Ventures, with participation from Salvo’s original Seed investors (Threshold Ventures, Torch Capital, and Felicis Ventures) and angel investors like Anmol Madan (founder of Ginger Health). Additionally, Rachel Parlier (City Light Capital) and Emily Melton (Threshold Ventures) will join Salvo’s Board of Directors, bringing extensive experience in healthcare innovation.
– The investment will fuel the nationwide deployment of Salvo’s innovative “wraparound care” model for gastroenterology (GI) practices, health systems, and Accountable Care Organizations (ACOs).
Strengthening Local Care Delivery
Salvo’s model complements existing care provided by local gastroenterologists, health systems, and Accountable Care Organizations (ACOs). They achieve this by:
Offering telehealth and app-based support: Providing patients with daily support and resources to manage their chronic conditions.
Empowering local providers: Addressing staff shortages and burnout by offering a team of nurses, dietitians, and behavioral health specialists.
Enabling insurance coverage: Supporting billing for Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) codes for both Medicare and commercially insured patients.
Focus on Interdisciplinary Care
Unlike some competitors, Salvo prioritizes collaboration with local providers, making them the hub of each patient’s personalized care plan. This interdisciplinary approach allows for:
– Improved patient outcomes: Research shows that 84% of patients report a better experience with Salvo compared to traditional care.
– Reduced healthcare utilization: Studies indicate a 79% decrease in GI-related ER and urgent care visits for patients enrolled in Salvo’s program.
– Cost savings for payers: A leading actuary study suggests Salvo has the potential to save payers $3 for every $1 spent on care.
Expanding to Address Metabolic Liver Disease
Salvo is expanding its services to include “wraparound care” for Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD). This increasingly prevalent condition requires specialized care that Salvo’s model is well-positioned to address:
Comprehensive care programs: Salvo offers a program specifically designed to support patients managing MASLD, complementing medication with behavioral health and nutrition guidance.
Addressing staffing shortages: Salvo leverages technology and automation to empower its care teams to support more patients effectively.